药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02269 药明生物

已收盘 10-28 16:08:25

46.320

+1.660

+3.72%

最高46.960	最低44.760	成交量3,599万
今开45.800	昨收44.660	日振幅4.93%
总市值1,907亿	流通市值1,907亿	总股本41.17亿
成交额16.60亿	换手率0.87%	流通股本41.17亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"药明生物","latestPrice":46.32,"timestamp":1793174905004,"preClose":44.66,"halted":0,"volume":35993940,"delay":0,"changeRate":0.03716972682489932,"floatShares":4117000000,"shares":4117000000,"eps":1.3664208762611605,"marketStatus":"已收盘","change":1.66,"latestTime":"10-28 16:08:25","open":45.8,"high":46.96,"low":44.76,"amount":1660216181,"amplitude":0.049261,"askPrice":46.32,"askSize":219000,"bidPrice":46.3,"bidSize":27500,"shortable":3,"etf":0,"ttmEps":1.3944147712651616,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793237400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1497283200000,"exchange":"SEHK","adjPreClose":44.66,"openAndCloseTimeList":[[1793151000000,1793160000000],[1793163600000,1793174400000]],"volumeRatio":0.895268,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK","impliedVol":0.0004,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/02269","defaultTab":"news","newsList":[{"id":"1107203752","title":"异动解读｜药明生物盘中上涨3.09%，FDA核查利好继续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1107203752","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107203752?lang=zh_cn&edition=full","pubTime":"2026-10-28 09:56","pubTimestamp":1793152616,"startTime":"0","endTime":"0","summary":"10月28日，药明生物盘中上涨3.09%，报46.04港元，成交额1.81亿港元。消息面上，公司此前披露无锡马山基地顺利通过美国FDA未预先通知的GMP现场核查，且无重大、关键缺陷，成为近期股价获得支撑的主要催化。该基地为中国首个获得FDA和EMA批准进行商业化生产的生物制药基地，覆盖多款已在美国获批上市的生物药品种全生产体系，显示公司质量管控体系再次获得高标准认可。与此同时，药明康德等生命科学工具和服务个股同步走强，也对股价形成带动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明生物获FDA认可，股价应声上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678114701","title":"一批绩优医疗基金披露三季报！重仓金斯瑞生物科技、凯莱英、药明生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2678114701","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678114701?lang=zh_cn&edition=full","pubTime":"2026-10-27 14:00","pubTimestamp":1793080809,"startTime":"0","endTime":"0","summary":"10月27日，招商基金、前海开源基金旗下部分产品发布季报。招商前沿医疗保健、招商品质成长和前海开源医疗健康三季度收益分别为46.6%、45.19%、34.19%（统计A份额），分别在普通股票型、偏股混合型和灵活配置型基金中排名第一。重仓股方面，前海开源医疗健康季内加仓了金斯瑞生物科技、药明生物等个股；招商前沿医疗保健加仓A股药明康德、凯莱英等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610273909580934.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610273909580934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0132","LU1328615791.USD","LU0326950275.SGD","BK1521","LU0029874061.USD","LU0327786744.USD","LU1794554557.SGD","LU1880383366.USD","LU2476274308.USD","LU2039709279.SGD","162412","LU0320764599.SGD","BK1141","LU0348827113.USD","LU1961090484.USD","002821","LU0856984785.SGD","LU0052750758.USD","LU0516423091.SGD","LU1242518857.USD","BK0239","LU0348735423.USD","LU1720050803.USD","LU0359201612.USD","LU0588546209.SGD","LU0708995583.HKD","06821","LU0572944931.SGD","SG9999002562.SGD","LU0540923850.HKD","LU0516422440.USD","BK1191","LU2399975544.HKD","LU1688375341.USD","IE00B0JY6N72.USD","LU0417516902.SGD","02269","LU0039217434.USD","KURE","LU0128526141.USD","LU0708995153.HKD","LU0516422366.SGD","IE00BFMHRM44.USD","LU0359202008.SGD","LU0181495838.USD","SG9999002463.SGD","LU0634319403.HKD","LU0979878070.USD","LU0128522744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105136139","title":"异动解读｜药明生物盘中下跌3.79%，瑞银下调评级至中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1105136139","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105136139?lang=zh_cn&edition=full","pubTime":"2026-10-27 09:53","pubTimestamp":1793066008,"startTime":"0","endTime":"0","summary":"10月27日，药明生物盘中下跌3.79%，报44.16港元，成交额2.07亿港元。消息面上，瑞银近日将公司评级下调至中性，并给出27元人民币目标价，成为股价承压的直接催化。尽管公司此前披露中期实现营收117.87亿元、经调整净利润39.37亿元，且无锡马山基地顺利通过美国FDA未预先通知的GMP现场核查，但投行观点转谨慎后，短线情绪仍受压，同行药明康德、药明合联等亦同步偏弱。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明生物盘中走弱，瑞银下调评级","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678011055","title":"广发基金刘杰旗下港股创新药ETF广发三季报最新持仓，重仓药明生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2678011055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678011055?lang=zh_cn&edition=full","pubTime":"2026-10-27 07:45","pubTimestamp":1793058329,"startTime":"0","endTime":"0","summary":"证券之星消息，10月27日广发基金旗下刘杰管理的广发中证香港创新药交易型开放式指数基金(QDII)公布三季报，近1年净值增长率-10.4%。与上一季度相比，该基金前十大重仓股新增金斯瑞生物-一千，药明合联；其中药明生物持仓占比10.35%，为该基金第一大重仓股；三生制药，科伦博泰生物等退出前十大重仓股；详细数据如下：本文数据来源于港股创新药ETF广发三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700009804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0029874905.USD","LU0359202008.SGD","BK1610","LU0516422952.EUR","BK1576","LU0348825331.USD","LU0979878070.USD","LU0052750758.USD","LU0516422366.SGD","LU0456846285.SGD","BK1521","LU1794554557.SGD","LU0039217434.USD","LU0051755006.USD","LU1242518931.SGD","LU0359201612.USD","SG9999002562.SGD","02269","LU0211977185.USD","KURE","LU2476274308.USD","LU2399975544.HKD","LU0320764243.SGD","LU0708995153.HKD","LU0181495838.USD","LU0823426480.USD","LU3063872942.SGD","BK1589","SG9999011746.SGD","LU2476274720.SGD","SG9999002463.SGD","LU0540923850.HKD","LU0348827113.USD","LU0043850808.USD","LU0856984785.SGD","LU0708995583.HKD","LU0819121731.USD","LU1242518857.USD","IE00B0JY6N72.USD","LU0417516902.SGD","LU0516423091.SGD","LU0456827905.SGD","LU0823426308.USD","IE00BFMHRM44.USD","LU0572944931.SGD","BK1141","LU0588546209.SGD","LU0128526141.USD","513120","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678469117","title":"港股概念追踪 | 药明康德再度上调2026全年业绩指引 机构：持续看好创新药出海趋势(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2678469117","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678469117?lang=zh_cn&edition=full","pubTime":"2026-10-27 07:20","pubTimestamp":1793056823,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，10月26日晚间，药明康德公告，第三季度营业收入为166.40亿元，同比增长38.01%；归属于上市公司股东的净利润为83.18亿元，同比增长136.67%，并进一步上调2026年全年业绩指引。这是药明康德16个月内第四次上调全年经营目标。今年以来，药明康德在手订单先后突破600亿、700亿关口，持续刷新纪录。截至2026年9月末，其持续经营业务在手订单攀升至767.4亿元，同比增长36.4%。其中第二季度实现营业收入40.17亿元，股东应占溢利4.15亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0540923850.HKD","LU0326950275.SGD","LU0823426480.USD","LU2399975544.HKD","LU0140636845.USD","KCAI","BK1141","LU0823426308.USD","LU0348735423.USD","03759","LU1303224171.USD","MEDX","603259","LU0572944931.SGD","LNGR","LU2125910500.SGD","LU0348767384.USD","06821","02269","IE00B0JY6N72.USD","IBBQ","BK1583","LU0320764243.SGD","LU1997245094.SGD","LU0348766576.USD","BK4588","159992","BK1610","IE00BFMHRM44.USD","LU1719994722.HKD","VXUS","LU0051755006.USD","LU0359201612.USD","LU1794554557.SGD","02359","SG9999011746.SGD","KURE","BK1161","LU0072913022.USD","LU0516422366.SGD","IE00B5MMRT66.SGD","LU1720050803.USD","06978","LU1242518857.USD","LU1969619763.USD","LU1251922891.USD","LU1255011170.USD","LU0359202008.SGD","LU2242644610.SGD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177142918","title":"异动解读｜药明生物盘中下跌3.06%，瑞银下调评级至中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1177142918","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177142918?lang=zh_cn&edition=full","pubTime":"2026-10-26 10:38","pubTimestamp":1792982338,"startTime":"0","endTime":"0","summary":"10月26日，药明生物盘中下跌3.06%，报44.44港元，成交额4.36亿港元。消息面上，瑞银此前将公司评级下调至中性，并给出27元人民币目标价，成为近期股价承压的直接催化。尽管公司此前披露中期实现营收117.87亿元、经调整净利润39.37亿元，且无锡马山基地顺利通过美国FDA未预先通知的GMP现场核查，但投行观点转谨慎后，短线情绪持续受压，药明康德、药明合联等同行当日亦普遍走弱。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明生物走低，瑞银下调评级","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677481109","title":"ESMO年会开幕，创新药快速拉升，恒生生物科技指数翻红","url":"https://stock-news.laohu8.com/highlight/detail?id=2677481109","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677481109?lang=zh_cn&edition=full","pubTime":"2026-10-23 13:56","pubTimestamp":1792734960,"startTime":"0","endTime":"0","summary":"10月23日午后，港股三大指数集体拉升，恒生科技指数一度涨超2%，恒生国企指数、恒生指数跟涨；恒生生物科技指数午后翻红，亚盛医药、翰森制药、科伦博泰生物、先声药业、康方生物等盘中涨幅 ...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261023/c681018111.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261023/c681018111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["03613","IBBQ","BK1161","MEDX","03737","03347","02269","01666","159992","BK1574","06606","06127","02359","06978","02273","01643","03759","09926","LNGR","06160","00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116651693","title":"异动解读｜药明生物盘中下跌3.31%，瑞银下调评级至中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1116651693","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116651693?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:35","pubTimestamp":1792719311,"startTime":"0","endTime":"0","summary":"10月23日，药明生物盘中下跌3.31%，报43.76港元，成交额1.79亿港元。消息面上，瑞银近日将公司评级下调至中性，目标价27元人民币，成为本次股价走弱的直接催化。公司此前虽披露中期实现营收117.87亿元、经调整净利润39.37亿元，且无锡马山基地通过美国FDA GMP现场核查，但最新评级调整对短线情绪形成压制，同行药明康德、药明合联及晶泰控股当日亦普遍走弱。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明生物盘中走弱，瑞银下调评级","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199376240","title":"异动解读｜药明生物盘中下跌3.12%，报47.9港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199376240","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199376240?lang=zh_cn&edition=full","pubTime":"2026-10-22 10:09","pubTimestamp":1792634961,"startTime":"0","endTime":"0","summary":"10月22日，药明生物盘中下跌3.12%，报47.9港元，成交额3.11亿港元。药明生物所在的生命科学工具和服务行业中，金斯瑞生物-一千跌0.17%，药明康德跌1.94%，英矽智能跌5.85%，药明合联跌2.89%，晶泰控股跌2.38%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677064342","title":"港股开盘强势 恒指高开1.14% 联想集团（00992）涨6.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677064342","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677064342?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:27","pubTimestamp":1792546075,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘强势，恒指高开1.14%，国企指数高开1.36%，恒生科技指数高开1.60%。福耀玻璃低开1.54%，公司公告公布截至2026年9月30日止第三季报，归属于上市公司股东的净利润20.36亿元，同比减少9.87%；归属于上市公司股东的扣除非经常性损益的净利润20.00亿元，同比减少9.71%。期内，集团营业收入121.52亿元，同比增长2.51%。中泰国际表示，美国股市昨晚三大指数涨跌不一，道指与标普500指数分别上涨1.0%与0.3%，纳指下跌0.02%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjE5MTg4YjVmOWZlYmUxNDMyNzYzODgyMzAy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjE5MTg4YjVmOWZlYmUxNDMyNzYzODgyMzAy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994062","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU1770034418.SGD","LU0181495838.USD","LU0072913022.USD","LU0370786039.SGD","LU0634319403.HKD","BK1576","LU0140636845.USD","BK1610","LU2778985437.USD","LU0516423091.SGD","LU0320764755.SGD","LU0819121731.USD","LU1046422090.SGD","LU0633140560.USD","LU0890818403.SGD","80992","LU1251922891.USD","BK1575","06809","LU0128526141.USD","LU0862451837.USD","LU1880383366.USD","LU2399975544.HKD","LU2039709279.SGD","LU0880133367.SGD","LU0128522157.USD","688235","LU0456846285.SGD","LU2476274308.USD","LU0672654166.SGD","LU0791590937.USD","LU0455707207.USD","LU1366334578.USD","HK0000320223.HKD","LU1688375341.USD","LU1969619763.USD","LU0348825331.USD","LU1785774172.SGD","BK1583","LU0228659784.USD","LU0052756011.USD","HK0000306701.USD","LU2242644610.SGD","LU0683595622.HKD","LU1993786604.SGD","LU1808992512.USD","LU0823426308.USD","LU0348735423.USD","LU0359201612.USD","KURE","BK1163","IE0032431581.USD","02015","LU1720050803.USD","01801","06160","LU0128525689.USD","LU0828237510.HKD","LU0502904849.HKD","LU0633140727.USD","LU2097828714.EUR","BK1119","LU0029874061.USD","LU1188198961.HKD","LU0052750758.USD","BK1587","LU0320764599.SGD","LU2476274720.SGD","LU0043850808.USD","LU0572940350.SGD","BK1539","LU1242518931.SGD","LNVGY","IE00B0JY6N72.USD","LU1242518857.USD","LU2328871848.SGD","LU0320764243.SGD","LU0862451753.SGD","LU1152091168.USD","IDRV","LU0039217434.USD","LU1267930227.SGD","LU0516423174.USD","BK1193","LU0417516738.SGD","LU0051755006.USD","LU0359202008.SGD","LU0310800965.SGD","LU0708995583.HKD","BK1589","LU0029874905.USD","LU0417516902.SGD","LU0501845795.SGD","ONC","HK0000306685.HKD","LU0048580855.USD","LU0348827113.USD","TCHI","LU2097828805.USD","BK1521","LU0572939691.SGD","LU0972618739.USD","LU2097828631.EUR","LU0327786744.USD","LU1719994722.HKD","LU1152091754.HKD","LU0456827905.SGD","BK1161","BK1588","LU0049112450.USD","WXXWY","LU0463099449.HKD","LU1303224171.USD","688008","LU0708995153.HKD","LU0067412154.USD","LU0029875118.USD","LU1961090484.USD","LU0823426480.USD","LU0516422440.USD","BK1607","LU0588546209.SGD","LU0979878070.USD","LU0128522744.USD","LU2097828474.EUR","LU2097828557.USD","IE0003895053.USD","BK1500","IE0034224299.USD","LU3063872942.SGD","LU0543330483.HKD","LU0244354667.USD","LU0561508036.HKD","LU1960683339.HKD","HK0000320264.USD","SG9999002463.SGD","LI","LU0307460666.USD","BK1526","LU0264606111.USD","LU1008478684.HKD","LU1794554557.SGD","SG9999002562.SGD","LU0572944931.SGD","LU1235295612.USD","LU2488822045.USD","LU0149534421.HKD","00992","LU0516422366.SGD","LU0211977185.USD","LU0607220059.USD","LU1807302812.USD","02269","LU0540923850.HKD","LU0326950275.SGD","LU1831875114.USD","LU0516422952.EUR","LU0856984785.SGD","LU1366334651.USD","BK1141","LU0791591158.USD","SG9999011746.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677643406","title":"【券商聚焦】国金证券：创新药板块迎来业绩兑现与国际化重估共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2677643406","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677643406?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:16","pubTimestamp":1792545406,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指出，创新药前沿技术加速迭代，IO2.0、ADC迭代、自免长效双抗等重塑治疗格局。中国原研资产深度融入全球交易，国际化步入收获期。支付端医保与商保双轮驱动，国谈优化准入，商保目录落地缓解高值药进院约束，本土Biotech净现金流改善、迎来盈亏平衡拐点。海内外政策聚焦真创新，生物类似药温和集采兑现。优质管线梯队完备，百济神州、康方生物、科伦博泰等核心分子加速欧美商业化，创新药板块迎来业绩兑现与国际化重估共振。风险提示：BD受海外地缘政策约束风险；创新药行业竞争加剧风险；医保控费降价不及预期风险；海外流动性收紧风险。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994055","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","MEDX","09995","LNGR","LU1303224171.USD","LU0823426308.USD","BK1589","LU1807302812.USD","06185","LU0128522744.USD","LU1951186391.HKD","LU0588546209.SGD","02269","LU0456846285.SGD","LU0880133367.SGD","LU0348784397.USD","IE00B0JY6N72.USD","LU0516422366.SGD","LU0320764599.SGD","LU1794554557.SGD","BK1141","KCE","02616","IBBQ","06978","KURE","LU0516422440.USD","LU2097828714.EUR","600109","LU1226288170.HKD","IE0008368742.USD","LU0455707207.USD","LU0417516571.SGD","IE00B031HY20.USD","LU0128526141.USD","BK0183","159992","09926","LU0348783233.USD","IE00BPRC5H50.USD","06160","LU0228659784.USD","BK1574","LU0540923850.HKD","02142","LU1770034418.SGD","09688","01877","01093","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676665575","title":"创新药概念强势 翰森制药（03692）涨逾7% 前三季对外技术授权约1300亿美元接近25年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2676665575","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676665575?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:23","pubTimestamp":1792466598,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念强势，截至发稿，乐普生物 涨8.81%，翰森制药涨7.06%，药明生物涨6.74%，晶泰控股涨4.56%，康诺亚-B涨4.70%，亚盛医药涨4.30%，恒瑞医药涨4.16%，药明合联涨3.96%，云顶新耀涨3.89%，和黄医药涨3.68%，中国生物制药涨3.24%，石药集团涨3.16%，科伦博泰生物涨3.14%，诺诚健华涨3.08%。消息面上，据人民财讯，10月20日，国家发展改革委召开10月份新闻发布会，会上提到，我国前三季度创新药对外技术授权约1300亿美元，接近去年全年。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993987","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","LU0417516902.SGD","LU0417516738.SGD","MEDX","LU0128522744.USD","02269","02228","LU0348827113.USD","03692","LU0979878070.USD","02157","LU1242518931.SGD","LU2476274720.SGD","06855","09969","00013","LU1008478684.HKD","LU1720050803.USD","01177","BK1521","LU2488822045.USD","159992","02162","LU0196878994.USD","BK1589","LU0211977185.USD","BK1576","01093","06990","LU1993786604.SGD","LU1226288170.HKD","LU1152091754.HKD","IE0008369823.USD","LU1188198961.HKD","LU2543165471.USD","KURE","IBBQ","06978","LU0072913022.USD","BK1610","LU1794554557.SGD","BK1161","LU0588546209.SGD","01276","01952","LU1242518857.USD","LU0359201885.HKD","02268","LNGR","LU0043850808.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676655975","title":"港股异动 | 药明生物(02269.HK)早盘涨近7% 无锡马山基地顺利通过美国FDA GMP现场核查","url":"https://stock-news.laohu8.com/highlight/detail?id=2676655975","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676655975?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:10","pubTimestamp":1792465807,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0708995153.HKD","LU0181495838.USD","LU0039217434.USD","LU0979878070.USD","LU1242518857.USD","LU2778985437.USD","SG9999002562.SGD","LU0456827905.SGD","LU0348825331.USD","LU0417516738.SGD","LU0359202008.SGD","LU0856984785.SGD","LU2476274720.SGD","LU3063872942.SGD","LU0572944931.SGD","LU0029874905.USD","LU1688375341.USD","IE00B0JY6N72.USD","LU0516422366.SGD","LU0819121731.USD","LU2039709279.SGD","LU1242518931.SGD","LU0417516902.SGD","BK1589","LU0708995583.HKD","BK1141","LU0043850808.USD","LU0029874061.USD","LU0140636845.USD","LU0211977185.USD","KURE","02269","BK1610","LU0823426480.USD","LU0823426308.USD","LU0516423174.USD","LU0327786744.USD","LU0516422952.EUR","LU0359201612.USD","LU0516423091.SGD","BK1576","LU1794554557.SGD","LU0348735423.USD","LU0348827113.USD","LU0326950275.SGD","LU0051755006.USD","LU0128522744.USD","LU0588546209.SGD","LU0320764599.SGD","SG9999011746.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676365597","title":"港股异动 | 药明生物(02269)早盘涨近7% 无锡马山基地顺利通过美国FDA GMP现场核查","url":"https://stock-news.laohu8.com/highlight/detail?id=2676365597","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676365597?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:10","pubTimestamp":1792465807,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药明生物早盘涨近7%。消息面上，药明生物近期宣布，无锡马山基地顺利通过美国FDA未预先通知的GMP现场核查，本次核查无重大、关键缺陷，顺利关厂。核查覆盖基地多款已在美国获批上市的生物药品种全生产体系，公司质量管控体系再次获得全球最高药监标准认可。公开资料显示，药明生物无锡马山基地是中国首个获得FDA和EMA批准进行商业化生产的生物制药基地，也是公司原液与制剂协同运营的重要生产基地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274720.SGD","LABU","LU0516423174.USD","LU1242518857.USD","LU0417516738.SGD","LU0128526141.USD","LU0043850808.USD","LU0708995153.HKD","LU0327786744.USD","BK1576","BK1610","KCAI","LU0128522744.USD","LU1242518931.SGD","IE00B0JY6N72.USD","LU0634319403.HKD","LU0029874061.USD","LU0029874905.USD","LU0823426480.USD","LU0856984785.SGD","LU1880383366.USD","LU1961090484.USD","VXUS","LU0572944931.SGD","LU0540923850.HKD","LU0516422952.EUR","LU0823426308.USD","LU0307460666.USD","BK1141","LU0181495838.USD","LU1794554557.SGD","SG9999002463.SGD","LU0348735423.USD","02269","BK1521","LU0708995583.HKD","SG9999002562.SGD","LU0588546209.SGD","LU0516422366.SGD","BK4588","KURE","LU0359201612.USD","LU2039709279.SGD","LU0348825331.USD","BK1589","LU0979878070.USD","LU0819121731.USD","LU0561508036.HKD","LU0516423091.SGD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108565710","title":"异动解读｜药明生物盘中上涨3.36%，CXO板块回暖叠加中期业绩稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=1108565710","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108565710?lang=zh_cn&edition=full","pubTime":"2026-10-20 09:55","pubTimestamp":1792461335,"startTime":"0","endTime":"0","summary":"10月20日，药明生物盘中上涨3.36%，报49.82港元，成交额3.07亿港元。此次异动主要受CXO及生物医药板块回暖带动，同时公司中期业绩表现稳健，增强了市场对其基本面的信心。公司此前披露中期实现营收117.87亿元，经调整净利润39.37亿元，毛利率由42.7%升至46.2%，经营活动现金流42.87亿元，同比增长137.2%；其中生物药外部销售81.05亿元，同比增长11.3%，XDC外部销售36.82亿元，同比增长37.8%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明生物盘中上涨，CXO回暖叠加业绩稳健","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109072607","title":"创新药概念股续升，康诺亚涨超12%，云顶新耀涨超11%，金斯瑞生物涨近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109072607","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109072607?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:51","pubTimestamp":1792115499,"startTime":"0","endTime":"0","summary":"港股创新药概念股续升，康诺亚涨超12%，云顶新耀涨超11%，金斯瑞生物涨近8%，百济神州涨超6%，再鼎医药涨近5%，药明合联、药明生物涨超4%，药明康德涨近4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","06160","01548","09688","02269","02162","02359","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199519067","title":"异动解读｜药明生物盘中上涨3.52%，CXO板块回暖叠加中期业绩稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=1199519067","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199519067?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:38","pubTimestamp":1792114687,"startTime":"0","endTime":"0","summary":"10月16日，药明生物盘中上涨3.52%，报50.2港元，成交额1.3亿港元。消息面上，近期CXO及生物医药板块曾连续回调，药明生物此前随板块承压；随着板块情绪修复，同属产业链的药明康德、药明合联及金斯瑞生物科技等同步走强，带动公司股价反弹。基本面方面，公司中期实现营收117.87亿元，经调整净利润39.37亿元，毛利率升至46.2%，经营活动现金流增至42.87亿元，整体经营维持稳健。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药明生物盘中上涨，CXO板块回暖带动股价反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675546035","title":"【券商聚焦】中信建投：ESMO中国研究入选创新高 梳理医药细分板块机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2675546035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675546035?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:27","pubTimestamp":1792114033,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券表示，本周制药行业表现一般，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医疗器械及服务板块低值耗材表现较好，多受个股事件催化，科技概念标的调整，港股回购活跃；短期关注招标改善和集采出清，中长期看创新、出海、并购。中药板块跑赢申万医药及大盘，关注红利、创新及“四同药品”、中成药集采政策。生物制品板块跑输医药指数及大盘，AI制药、mRNA肿瘤疫苗概念股回调；南北方ILI%均环比降低，南方检测阳性率提升、北方降低。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993829","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","01801","BK1610","LU0501845795.SGD","01177","LU0072913022.USD","01093","LU0140636845.USD","LU1951186391.HKD","09688","BK1515","IE00BZ08YR35.GBP","LU1226287875.USD","06160","09926","LU1242518857.USD","601066","09939","KURE","LU0128526141.USD","SG9999002562.SGD","LU0417516902.SGD","06185","02142","SG9999011746.SGD","LU0359201612.USD","09995","LU1251922891.USD","LU0228659784.USD","LU2476274720.SGD","02616","LU0314109678.HKD","LU0823426480.USD","BK1583","LU0540923850.HKD","LU0348767384.USD","02269","159938","LU0819121731.USD","BK1141","LU0052750758.USD","LU0348827113.USD","LU0634319403.HKD","LU0181495838.USD","LU0979878070.USD","KCE","LU1226287792.SGD","BK1500","01877","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675376082","title":"【券商聚焦】中信建投：AI重塑药物研发 2035年全球市场有望破460亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675376082","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675376082?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:00","pubTimestamp":1792026019,"startTime":"0","endTime":"0","summary":"AI深度介入靶点识别、分子设计等药物研发环节，破解传统制药高投入、长周期难题。报告测算，全球AI制药市场2025年规模约24.9亿美元，2035年有望突破460亿美元，CAGR超33%，国内市场具备高增长潜力；科技巨头、药企、CXO等多方入局，海内外多家头部企业完成平台搭建与商业化验证。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993729","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","02616","LU0128526141.USD","LU0516423174.USD","01093","BK1588","LU0516422440.USD","02142","01801","LU0856984785.SGD","IBBJ","BK1500","CHAT","AIPO","IE00B031HY20.USD","LU0456827905.SGD","LU0588546209.SGD","06160","QTOC","09688","LU0501845795.SGD","BK1576","LU2778985437.USD","06185","LU0456846285.SGD","KURE","LU1152091754.HKD","LU1008478684.HKD","IE00BZ08YS42.EUR","SG9999002562.SGD","BK1141","LU0128522744.USD","09995","LU0979878070.USD","01177","ARTY","LU0051755006.USD","601066","LU0029874061.USD","AGIX","LU0516422952.EUR","VTHR","01877","LU0326950275.SGD","LU0348825331.USD","09926","LU0052750758.USD","LU1251922891.USD","LU2242644610.SGD","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113397424","title":"异动解读｜药明生物盘中下跌3.3%，生物医药板块延续回调叠加获利盘兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=1113397424","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113397424?lang=zh_cn&edition=full","pubTime":"2026-10-14 14:45","pubTimestamp":1791960337,"startTime":"0","endTime":"0","summary":"10月14日，药明生物盘中下跌3.3%，报49.6港元，成交额7.41亿港元。消息面上，港股生物医药板块近日持续走弱，CXO概念股普遍承压，资金在前期反弹后继续兑现收益，对公司股价形成拖累。公司此前披露中期业绩显示，营收117.87亿元，经调整净利润39.37亿元，毛利率升至46.2%，经营活动现金流增至42.87亿元，基本面整体稳健。生物药分部主要从事提供生物药的发现、开发和生产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药明生物回调，生物医药板块承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":-0.1077},{"period":"1month","weight":-0.1574},{"period":"3month","weight":0.1341},{"period":"6month","weight":0.3517},{"period":"1year","weight":0.198},{"period":"ytd","weight":0.4205}],"compareEarnings":[{"period":"1week","weight":-0.0346},{"period":"1month","weight":-0.0599},{"period":"3month","weight":-0.1072},{"period":"6month","weight":-0.1061},{"period":"1year","weight":-0.1283},{"period":"ytd","weight":-0.101}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明生物技术有限公司是一家主要从事向生物制剂行业的客户提供就生物发现、开发及生产的端到端解决方案及服务的投资控股公司。该公司主要通过两个分部运营其业务。生物药分部主要从事提供生物药的发现、开发和生产。药明合联（XDC）分部主要从事为抗体偶联药物（ADCs）及各种生物偶联药物提供合同研究、开发及生产组织（CRDMO）服务。该公司主要在国内和国外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052868},{"month":2,"riseRate":0.555556,"avgChangeRate":0.006907},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.001977},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000488},{"month":5,"riseRate":0.555556,"avgChangeRate":0.002485},{"month":6,"riseRate":0.666667,"avgChangeRate":0.061606},{"month":7,"riseRate":0.7,"avgChangeRate":0.085288},{"month":8,"riseRate":0.6,"avgChangeRate":0.053299},{"month":9,"riseRate":0.7,"avgChangeRate":0.065466},{"month":10,"riseRate":0.4,"avgChangeRate":-0.05059},{"month":11,"riseRate":0.444444,"avgChangeRate":0.025584},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009161}],"exchange":"SEHK","name":"药明生物","nameEN":"WUXI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明生物,02269,药明生物股票,药明生物股票老虎,药明生物股票老虎国际,药明生物行情,药明生物股票行情,药明生物股价,药明生物股市,药明生物股票价格,药明生物股票交易,药明生物股票购买,药明生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明生物(02269)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明生物(02269)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}